Specialist Physicians’ Perspectives on State PDABs: Access, Affordability, and Administrative Burden
Specialists voice concerns about how PDABs may limit patient access.
As states expand PDAB authority to set Upper Payment Limits (UPLs) on high-cost therapies, Magnolia Market Access surveyed physicians in Colorado, Maryland, Oregon, and Washington to understand how these policies may affect prescribing decisions, patient care, and clinical operations.
Key findings:
- Specialists report major gaps in communication between PDABs and providers
- Physicians anticipate increased administrative burden and disruptions to care
- Concerns emerge around treatment access, clinical autonomy, and non-medical switching
- Most believe key decisions are being made without adequate clinical input
Download the full white paper, State Prescription Drug Affordability Boards (PDAB) and Analysis of Patient Impact: A US Physician Survey Study, or data, direct physician quotes, and insights into how PDABs may influence clinical decision-making, care delivery, and access strategy.
